102ND GENERAL ASSEMBLY
State of Illinois
2021 and 2022
HB3048

 

Introduced 2/19/2021, by Rep. Adam Niemerg

 

SYNOPSIS AS INTRODUCED:
 
20 ILCS 2310/2310-578 new

    Amends the Department of Public Health Powers and Duties Law of the Civil Administrative Code of Illinois. Requires the Department of Public Health to create and maintain a list of each immunizing agent derived from aborted fetal tissue and any alternative immunizing agents. Provides that the Department shall ensure that, before administering an immunizing agent derived from aborted fetal tissue to an individual, a health care provider shall provide to the individual or, if the individual is a child, to the parent, guardian, or person in loco parentis of the child: (1) notification that the immunizing agent was derived from aborted fetal tissue; (2) if an immunizing agent that is not an immunizing agent derived from aborted fetal tissue is available as an alternative to an immunizing agent derived from aborted fetal tissue, an offer of the alternative; and (3) notification of the option to decline the receipt of the immunizing agent. Effective immediately.


LRB102 13915 CPF 19266 b

FISCAL NOTE ACT MAY APPLY

 

 

A BILL FOR

 

HB3048LRB102 13915 CPF 19266 b

1    AN ACT concerning health.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Department of Public Health Powers and
5Duties Law of the Civil Administrative Code of Illinois is
6amended by adding Section 2310-578 as follows:
 
7    (20 ILCS 2310/2310-578 new)
8    Sec. 2310-578. Immunizing agents derived from aborted
9fetal tissue.
10    (a) As used in this Section:
11    "Health care provider" means any physician, advanced
12practice registered nurse, physician assistant, hospital
13facility, or other person that is licensed or otherwise
14authorized to deliver health care services.
15    "Immunizing agent derived from aborted fetal tissue" means
16an immunizing agent that is manufactured using a human fetal
17or embryonic cell line, protein, deoxyribonucleic acid,
18recombinant deoxyribonucleic acid, monoclonal antibody, or any
19other component derived from an elective abortion or using a
20cell line derived from the tissue of a fetus that was
21electively aborted.
22    (b) The Department shall create and maintain a list of
23each immunizing agent derived from aborted fetal tissue. If an

 

 

HB3048- 2 -LRB102 13915 CPF 19266 b

1immunizing agent that is not an immunizing agent derived from
2aborted fetal tissue is available as an alternative to an
3immunizing agent derived from aborted fetal tissue, the
4Department shall include the alternative on the list. The
5Department shall update the list annually and make the list
6available to the public on the Department's website.
7    (c) The Department shall ensure that, beginning January 1,
82022, before administering an immunizing agent derived from
9aborted fetal tissue to an individual, a health care provider
10shall notify the individual or, if the individual is a child,
11the parent, guardian, or person in loco parentis of the child
12that the immunizing agent was derived from aborted fetal
13tissue. If an immunizing agent that is not an immunizing agent
14derived from aborted fetal tissue is available as an
15alternative to an immunizing agent derived from aborted fetal
16tissue, the health care provider shall offer the alternative
17to the individual or, if the individual is a child, to the
18parent, guardian, or person in loco parentis of the child. A
19health care provider shall also notify the individual or, if
20the individual is a child, the parent, guardian, or person in
21loco parentis of the child of the option to decline the receipt
22of the immunizing agent.
 
23    Section 99. Effective date. This Act takes effect upon
24becoming law.